|
|
|
Insider
Information: |
Lampert Mark N |
Relationship: |
10% Owner |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
44 |
|
Direct
Shares |
110,838,010 |
|
Indirect Shares
|
88,557,834 |
|
|
Direct
Value |
$1,424,811,955 |
|
|
Indirect Value
|
$1,621,009,022 |
|
|
Total
Shares |
199,395,844 |
|
|
Total
Value |
$3,045,820,978 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
50
|
13
|
Stock
price went up :
|
40
|
4
|
Stock
price went down : |
10
|
9
|
|
|
|
Gain/Loss Ratio : |
4.0
|
4.0
|
Percentage
Gain/Loss : |
103.0%
|
-82.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Arena Pharmaceuticals Inc |
ARNA |
Director, 10% Owner |
2003-10-17 |
0 |
2003-10-17 |
4,520,212 |
Premium* |
|
Repligen Corp |
RGEN |
10% Owner |
2009-05-15 |
3,216,850 |
|
0 |
Premium* |
|
Dynavax Technologies Corp |
DVAX |
Indirect Beneficial Ow... |
2009-06-19 |
6,193,051 |
2009-06-19 |
18,579,153 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2009-09-22 |
4,123,551 |
2009-09-22 |
12,370,653 |
Premium* |
|
Gyre Therapeutics |
GYRE |
10% Owner |
|
0 |
2012-11-08 |
1,052,258 |
Premium* |
|
Arqule Inc |
ARQL |
10% Owner |
2018-05-30 |
771,305 |
2010-04-05 |
12,624,219 |
Premium* |
|
Astex Pharmaceuticals Inc |
ASTX |
10% Owner |
2010-04-20 |
5,583,399 |
2010-04-20 |
16,750,197 |
Premium* |
|
Capstone Therapeutics Corp |
CAPS |
See Explanation of Res... |
2011-06-27 |
0 |
2017-07-14 |
890,487 |
Premium* |
|
Ligand Pharmaceuticals Inc |
LGND |
See Explanation of Res... |
|
0 |
2014-03-25 |
130,175 |
Premium* |
|
Icagen Inc |
ICGN |
10% Owner |
2011-09-07 |
0 |
2011-09-07 |
625,400 |
Premium* |
|
Palatin Technologies Inc |
PTN |
10% Owner |
|
0 |
2014-02-27 |
2,494,521 |
Premium* |
|
Neurocrine Biosciences Inc |
NBIX |
10% Owner |
2011-10-10 |
0 |
2011-10-12 |
3,527,700 |
Premium* |
|
Kent International Inc |
KNTH |
See Explanation of Res... |
2011-12-23 |
0 |
2011-12-23 |
0 |
Premium* |
|
Chemocentryx, Inc. |
CCXI |
10% Owner |
|
0 |
2012-11-06 |
3,750,277 |
Premium* |
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
|
0 |
2013-06-07 |
7,761,738 |
Premium* |
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
2013-06-05 |
0 |
2015-02-05 |
1,898,293 |
Premium* |
|
Tobira Therapeutics Inc |
TBRA |
See Explanation of Res... |
|
0 |
2014-03-21 |
1,121,221 |
Premium* |
|
Cti Biopharma Corporation |
CTIC |
See Explanation of Res... |
2023-06-26 |
0 |
2023-06-26 |
0 |
Premium* |
|
Infinity Pharmaceuticals Inc |
INFI |
10% Owner |
2021-02-11 |
534,847 |
2016-12-01 |
0 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2023-01-06 |
1,693,924 |
2023-01-06 |
361,774 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2017-06-20 |
201,811 |
2017-05-09 |
0 |
Premium* |
|
Glycomimetics Inc |
GLYC |
10% Owner |
2020-11-04 |
630,453 |
|
0 |
Premium* |
|
Xenon Pharmaceuticals Inc. |
XENE |
10% Owner |
2018-03-27 |
59,464 |
2017-06-06 |
0 |
Premium* |
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2019-06-10 |
169,589 |
2017-10-19 |
0 |
Premium* |
|
Syndax Pharmaceuticals Inc |
SNDX |
10% Owner |
2018-06-18 |
85,038 |
2018-06-18 |
0 |
Premium* |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2018-12-04 |
370,391 |
2018-12-04 |
0 |
Premium* |
|
Pieris Pharmaceuticals, Inc. |
PIRS |
10% Owner |
2023-05-11 |
20,333,557 |
2019-01-30 |
0 |
Premium* |
|
Calithera Biosciences, Inc. |
CALA |
10% Owner |
2020-05-21 |
480,432 |
|
0 |
Premium* |
|
Five Prime Therapeutics Inc |
FPRX |
10% Owner |
2021-03-04 |
6,262,085 |
|
0 |
Premium* |
|
Cytokinetics Inc |
CYTK |
See Explanation of Res... |
2020-12-09 |
463,244 |
2019-12-10 |
0 |
Premium* |
|
Merus Nv |
MRUS |
10% Owner |
2021-10-08 |
232,747 |
|
0 |
Premium* |
|
Ideaya Biosciences, Inc. |
IDYA |
See Explanation of Res... |
2021-02-02 |
233,150 |
2020-06-19 |
0 |
Premium* |
|
Kymera Therapeutics, Inc. |
KYMR |
See Remarks and Footno... |
2023-11-03 |
294,632 |
2020-08-21 |
0 |
Premium* |
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
10% Owner |
2024-05-09 |
220,460 |
|
0 |
Premium* |
|
Olema Pharmaceuticals, Inc. |
OLMA |
Director, 10% Owner |
2023-09-12 |
524,151 |
2023-09-14 |
99,556 |
Premium* |
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2020-12-18 |
5,468,599 |
|
0 |
Premium* |
|
Rain Therapeutics Inc. |
RAIN |
See Remarks; Former 10... |
2024-01-25 |
0 |
2021-04-23 |
0 |
Premium* |
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2023-11-16 |
548,938 |
|
0 |
Premium* |
|
Verastem, Inc. |
VSTM |
10% Owner |
2022-01-25 |
19,630,934 |
|
0 |
Premium* |
|
ESSA Pharma Inc |
EPIX |
10% Owner |
2022-07-11 |
8,561,841 |
|
0 |
Premium* |
|
Third Harmonic Bio, Inc. |
THRD |
10% Owner |
2022-12-20 |
241,309 |
2022-12-20 |
0 |
Premium* |
|
Structure Therapeutics Inc. |
GPCR |
10% Owner |
2023-05-10 |
5,173,941 |
|
0 |
Premium* |
|
Engene Holdings Inc. |
ENGN |
10% Owner |
2023-10-31 |
2,221,445 |
|
0 |
Premium* |
|
Allakos Inc. |
ALLK |
10% Owner |
2024-01-16 |
16,312,872 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
356 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 9 of 15
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ASTX |
Astex Pharmaceuticals Inc |
Direct Beneficial Owner |
|
2010-04-20 |
4 |
S |
$3.54 |
$368,306 |
D/D |
(104,000) |
5,583,399 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-17 |
4 |
S |
$1.70 |
$183,600 |
D/D |
(108,000) |
4,771,551 |
0 |
- |
|
CASC |
Cascadian Therapeutics, I... |
See Explanation of Responses |
|
2013-06-07 |
4 |
B |
$1.83 |
$212,788 |
I/I |
116,252 |
2,377,517 |
1.5 |
- |
|
CYTK |
Cytokinetics Inc |
10% Owner |
|
2019-12-11 |
4 |
B |
$9.52 |
$1,126,700 |
D/D |
118,413 |
499,312 |
2.45 |
- |
|
RAIN |
Rain Therapeutics Inc. |
10% Owner |
|
2021-05-21 |
4 |
B |
$15.94 |
$1,944,701 |
D/D |
121,986 |
112,353 |
2.45 |
- |
|
ICGN |
Icagen Inc |
10% Owner |
|
2011-09-07 |
4 |
B |
$6.00 |
$760,707 |
I/I |
126,700 |
625,400 |
1.5 |
- |
|
CALA |
Calithera Biosciences, In... |
10% Owner |
|
2019-11-14 |
4 |
B |
$3.37 |
$433,005 |
D/D |
128,488 |
658,531 |
2.45 |
- |
|
CASC |
Cascadian Therapeutics, I... |
See Explanation of Responses |
|
2013-11-01 |
4 |
B |
$1.78 |
$229,620 |
I/I |
129,000 |
2,670,520 |
1.5 |
- |
|
FPRX |
Five Prime Therapeutics I... |
10% Owner |
|
2019-12-09 |
4 |
B |
$4.02 |
$542,363 |
D/D |
135,000 |
504,002 |
2.45 |
- |
|
FPRX |
Five Prime Therapeutics I... |
10% Owner |
|
2019-10-24 |
4 |
B |
$3.74 |
$506,987 |
D/D |
135,388 |
344,472 |
2.45 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-16 |
4 |
S |
$1.71 |
$235,566 |
D/D |
(138,000) |
4,879,551 |
0 |
- |
|
MRUS |
Merus Nv |
10% Owner |
|
2020-09-15 |
4 |
B |
$11.75 |
$1,724,360 |
D/D |
146,754 |
382,784 |
2.45 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
10% Owner |
|
2014-02-20 |
4 |
S |
$73.05 |
$10,730,737 |
I/I |
(146,900) |
79,390 |
0 |
- |
|
MRUS |
Merus Nv |
10% Owner |
|
2021-10-08 |
4 |
S |
$27.79 |
$4,092,034 |
D/D |
(147,267) |
232,747 |
0 |
% |
|
INFI |
Infinity Pharmaceuticals ... |
Director |
|
2016-12-01 |
4 |
B |
$1.18 |
$176,365 |
D/D |
148,894 |
547,554 |
3.92 |
- |
|
RPTX |
Repare Therapeutics Inc. |
10% Owner |
|
2022-06-13 |
4 |
B |
$12.73 |
$1,898,820 |
D/D |
149,161 |
412,604 |
2.45 |
- |
|
KYMR |
Kymera Therapeutics, Inc. |
See Remarks and Footnotes |
|
2022-05-05 |
4 |
B |
$19.60 |
$2,939,865 |
D/D |
150,000 |
212,604 |
2.39 |
- |
|
XENE |
Xenon Pharmaceuticals Inc... |
10% Owner |
|
2017-06-06 |
4 |
B |
$3.75 |
$565,909 |
D/D |
150,909 |
263,577 |
2.45 |
- |
|
CASC |
Cascadian Therapeutics, I... |
10% Owner |
|
2014-12-17 |
4 |
B |
$1.73 |
$266,022 |
I/I |
153,495 |
3,298,293 |
1.5 |
- |
|
CASC |
Cascadian Therapeutics, I... |
See Explanation of Responses |
|
2013-08-01 |
4 |
B |
$1.78 |
$282,296 |
I/I |
158,344 |
2,413,220 |
1.5 |
- |
|
MRUS |
Merus Nv |
10% Owner |
|
2020-12-18 |
4 |
B |
$16.05 |
$2,568,000 |
D/D |
160,000 |
2,245,067 |
2.45 |
% |
|
INFI |
Infinity Pharmaceuticals ... |
10% Owner |
|
2018-12-13 |
4 |
B |
$1.20 |
$209,913 |
D/D |
175,000 |
6,631,136 |
2.45 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
See Explanation of Responses |
|
2011-08-08 |
4 |
B |
$11.20 |
$1,969,663 |
I/I |
175,800 |
1,354,736 |
1.5 |
- |
|
CASC |
Cascadian Therapeutics, I... |
See Explanation of Responses |
|
2013-07-31 |
4 |
B |
$1.71 |
$307,307 |
I/I |
179,743 |
4,555,829 |
1.5 |
- |
|
MRUS |
Merus Nv |
10% Owner |
|
2020-09-10 |
4 |
B |
$11.10 |
$2,104,785 |
D/D |
189,651 |
372,526 |
2.45 |
% |
|
356 Records found
|
|
Page 9 of 15 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|